1 |
To receive and adopt the 2016 Annual Report |
3,554,183,464 |
97.22 |
101,455,389 |
2.78 |
3,655,638,853 |
4,387,214 |
2 |
Approve the Annual report on remuneration |
3,463,239,643 |
96.39 |
129,558,994 |
3.61 |
3,592,798,637 |
67,227,431 |
3 |
Approve the Remuneration policy |
3,422,452,218 |
95.23 |
171,330,252 |
4.77 |
3,593,782,470 |
66,243,598 |
4 |
Election of Emma Walmsley |
3,634,697,039 |
99.38 |
22,652,327 |
0.62 |
3,657,349,366 |
2,676,702 |
5 |
Election of Dr Vivienne Cox |
3,585,205,455 |
98.03 |
72,167,674 |
1.97 |
3,657,373,129 |
2,653,239 |
6 |
To elect Dr Patrick Vallance |
3,629,796,597 |
99.25 |
27,494,401 |
0.75 |
3,657,290,998 |
2,735,337 |
7 |
Re-election of Sir Philip Hampton |
3,628,585,104 |
99.22 |
28,393,827 |
0.78 |
3,656,978,931 |
3,047,437 |
8 |
Re-election of Professor Sir Roy Anderson |
3,625,292,635 |
99.12 |
32,058,752 |
0.88 |
3,657,351,387 |
2,674,980 |
9 |
Re-election of Vindi Banga |
3,581,285,228 |
97.92 |
76,000,048 |
2.08 |
3,657,285,276 |
2,741,092 |
10 |
Re-election of Simon Dingemans |
3,518,149,283 |
96.20 |
139,147,225 |
3.80 |
3,657,296,508 |
2,729,860 |
11 |
Re-election of Lynn Elsenhans |
3,638,701,603 |
99.49 |
18,607,222 |
0.51 |
3,657,308,825 |
2,710,187 |
12 |
Re-election of Dr Jesse Goodman |
3,639,142,174 |
99.50 |
18,139,405 |
0.50 |
3,657,281,579 |
2,714,188 |
13 |
Re-election of Judy Lewent |
3,510,396,677 |
95.98 |
146,948,919 |
4.02 |
3,657,345,596 |
2,680,772 |
14 |
Re-election of Urs Rohner |
3,575,150,146 |
97.76 |
82,080,983 |
2.24 |
3,657,231,129 |
2,795,239 |
15 |
Re-appointment of auditors |
3,589,897,930 |
98.70 |
47,405,837 |
1.30 |
3,637,303,767 |
22,722,600 |
16 |
Remuneration of auditors |
3,634,255,503 |
99.37 |
23,089,499 |
0.63 |
3,657,345,002 |
2,674,361 |
17 |
Authority for the company to make donations to political organisations and incur political expenditure |
3,590,068,747 |
98.21 |
65,556,654 |
1.79 |
3,655,625,401 |
4,400,967 |
18 |
Authority to allot shares |
3,545,752,292 |
96.96 |
111,083,355 |
3.04 |
3,656,835,647 |
3,190,721 |
19 |
Disapplication of pre-emption rights - general power*** |
3,579,962,643 |
97.94 |
75,432,563 |
2.06 |
3,655,395,206 |
4,624,157 |
20 |
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment*** |
3,395,638,484 |
92.96 |
257,114,976 |
7.04 |
3,652,753,460 |
7,265,904 |
21 |
Authority for the company to purchase its own shares*** |
3,607,672,499 |
98.68 |
48,202,613 |
1.32 |
3,655,875,112 |
4,151,256 |
22 |
Exemption from statement of senior statutory auditor's name |
3,629,354,814 |
99.28 |
26,480,369 |
0.72 |
3,655,835,183 |
4,198,037 |
23 |
Authorise reduced notice of a general meeting other than an AGM*** |
3,407,170,884 |
93.19 |
248,934,681 |
6.81 |
3,656,105,565 |
3,920,802 |
24 |
Approve the GlaxoSmithKline 2017 Performance Share Plan |
3,515,643,781 |
96.16 |
140,281,237 |
3.84 |
3,655,925,018 |
4,101,350 |
25 |
Approve the 2017 GlaxoSmithKline Deferred Annual Bonus Plan |
3,579,310,888 |
97.97 |
74,224,589 |
2.03 |
3,653,535,477 |
6,490,891 |